Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN86,7286,772,31
Msft0,37
Nokia4,2524,3-2,25
IBM-1,34
Mercedes-Benz Group AG52,9552,970,00
PFE-0,50
12.07.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 11.07.2025 22:00:00
Theravance Bioph-WI (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
11,30 -1,40 -0,16 171 940
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 12.07.2025
Popis společnosti
Obecné informace
Název společnostiTheravance Biopharma Inc
TickerTBPH
Kmenové akcie:Ordinary Shares
RICTBPH.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 97
Akcie v oběhu k 02.05.2025 50 001 332
MěnaUSD
Kontaktní informace
UliceUGLAND HOUSE, SOUTH CHURCH STREET
MěstoGEORGE TOWN
PSČKY1-1104
ZeměCayman Islands
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13456 508 086 000

Business Summary: Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Theravance Biopharma Inc revenues increased 6% to $15.4M. Net loss increased 16% to $13.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - bal increase of 54% to $6.5M (expense), Selling, general and administrative -bal increase of 12% to $14.6M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 12.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorRick Winningham65
Chief Financial Officer, Senior Vice PresidentAziz Sawaf43
Senior Vice President, General Counsel, SecretaryBrett Grimaud51
Senior Vice President - Commercial and Medical Affairs, Chief Business OfficerRhonda Farnum60
Senior Vice President - Development and Head of Ireland OfficeAine Miller48